Cell Source Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cell Source Inc (CLCS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Cell Source Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cell Source Inc | - | - | - | No |
| Competitors combined (42) | ||||
| High-Confidence Competitors (17) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CLCS Stock Performance relative to its Competitors
CLCS Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 2 | Tango Therapeutics Inc | 282.9% | Outperformed |
| 3 | Apellis Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Boundless Bio Inc | 282.9% | Outperformed |
| 5 | Fate Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cell Source Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cell Source Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cell Source Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cell Source Inc | 19.20 | - |
| Alnylam Pharmaceuticals Inc | 35,311.44 | 4,804.18 |
| United Therapeutics Corporation | 22,237.73 | 3,154.50 |
| Bridgebio Pharma Inc | 13,041.30 | 713.07 |
| Apellis Pharmaceuticals Inc | 5,392.33 | 1,105.28 |
| Crispr Therapeutics Ag | 5,220.45 | 13.39 |
| SUBTOTAL | 101,254.79 | 9,959.25 |
Sign in to see all competitors of Cell Source Inc .
Sources: Cell Source Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cell Source Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cell Source Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bellicum | Named by the company | 85% |
| City of Hope | Named by the company | 85% |
| Incyte | Named by the company | 85% |
| Merck (OncoImmune) | Named by the company | 85% |
| Takeda | Named by the company | 85% |
| Allovir | Named by the company | 85% |
| Bristol Myers Squibb | Named by the company | 85% |
| Fred Hutchinson | Named by the company | 85% |
| Kiadis | Named by the company | 85% |
| Orca | Named by the company | 85% |
| Abbvie | Named by the company | 85% |
| Bluebird | Named by the company | 85% |
| Dana Farber | Named by the company | 85% |
| Johns Hopkins | Named by the company | 85% |
| Molmed | Named by the company | 85% |
| Legend | Named by the company | 85% |
| Atara | Named by the company | 85% |
| Cellectis | Named by the company | 85% |
| Gilead (KITE) | Named by the company | 85% |
| Legend | Named by the company | 85% |
| Precision | Named by the company | 85% |
| Allogene | Named by the company | 85% |
| BMS/Celgene (JUNO) | Named by the company | 85% |
| Fate | Named by the company | 85% |
| Kadmon | Named by the company | 85% |
| Novartis | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cell Source Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cell Source Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bridgebio Pharma Inc | Reportable 100.00 % |
| Apellis Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Precigen Inc | Reportable 100.00 % |
| Uniqure N v | Single Reportable Segment 100.00 % |
| Verastem Inc | Research Developing and Commercialization Drugs Segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cell Source Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cell Source Inc | 19 | - | -4,719,087 |
| Alnylam Pharmaceuticals Inc | 35,311 | 1,921,673 | 323,195 |
| United Therapeutics Corporation | 22,238 | 2,253,214 | 936,357 |
| Bridgebio Pharma Inc | 13,041 | 849,903 | -836,732 |
| Apellis Pharmaceuticals Inc | 5,392 | 1,495,643 | 180,337 |
| Crispr Therapeutics Ag | 5,220 | 66,627 | -2,244,473 |
| PEERS TOTAL | 101,236 | 1,059,382 | -204,945 |
Cell Source Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| 23andme Holding Co | United States 90.26 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cell Source Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Cell Source Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cell Source Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Cell Source Inc | 21 | 0.00 % |
Market cap and industry share for the rest of Cell Source Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Cell Source Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | -0.8x | 4.5x | -5.3x |
| Return on Equity | 25.19 % | industry aggregate | 9.90 % |
| Return on Invested Capital | 18.49 % | -2.95 % (avg) | 21.44 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cell Source Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | 21.92 % | 18.80 % | 40.09 % | 26.22 % | 20.74 % | 37.73 % | 31.18 % | 21.79 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cell Source Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Cell Source Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cell Source Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cell Source Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 9.9 points above the industry aggregate.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (39.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-31.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cell Source Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cell Source Inc | 0.01 | 0.03 | - |
| Alnylam Pharmaceuticals Inc | 1.12 | 2.86 | 1.18 |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
| Bridgebio Pharma Inc | 1.25 | 1.80 | - |
| Apellis Pharmaceuticals Inc | 1.58 | 3.49 | 1.36 |
| Crispr Therapeutics Ag | 2.51 | 16.26 | 0.16 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cell Source Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cell Source Inc | Q1 2025 | - | - |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +66.9 % | - |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| Bridgebio Pharma Inc | Q2 2026 | +120.4 % | - |
| Apellis Pharmaceuticals Inc | Q1 2026 | +60.9 % | - |
| Crispr Therapeutics Ag | Q2 2026 | +1,041.4 % | - |
| PEERS TOTAL | +44.1 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cell Source Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cell Source Inc | Q1 2025 | - | - |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +110.0 % | +142.6 % |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
| Bridgebio Pharma Inc | Q2 2026 | +311.9 % | -91.3 % |
| Apellis Pharmaceuticals Inc | Q1 2026 | -14.5 % | - |
| Crispr Therapeutics Ag | Q2 2026 | - | +453.8 % |
Cell Source Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cell Source Inc | - | - | - |
| Alnylam Pharmaceuticals Inc | 15.76% | 22.10% | 93.61% |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
| Bridgebio Pharma Inc | - | - | - |
| Apellis Pharmaceuticals Inc | 13.20% | 17.94% | 39.71% |
| Crispr Therapeutics Ag | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cell Source Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cell Source Inc | - | - |
| Alnylam Pharmaceuticals Inc | 45.20 | 7.35 |
| United Therapeutics Corporation | 17.43 | 7.05 |
| Bridgebio Pharma Inc | - | 18.29 |
| Apellis Pharmaceuticals Inc | 39.45 | 4.88 |
| Crispr Therapeutics Ag | - | 389.82 |
| PEERS AVERAGE | - | 10.17 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.